Bernard J. Escudier
Santiago, RM, Chile
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 331 publications
Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.
Journal: European urology
Published: April 26, 2026
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 14, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 19, 2025
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.
Journal: Nature medicine
Published: April 19, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.
Journal: European urology
Published: March 24, 2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 21, 2025
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 29, 2025
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study.
Journal: European urology oncology
Published: October 11, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2024
Last Updated: 09/26/2026